Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 4 | Journal of Neuroinflammation

Fig. 4

From: Sac-1004, a vascular leakage blocker, reduces cerebral ischemia—reperfusion injury by suppressing blood–brain barrier disruption and inflammation

Fig. 4

Sac-1004 decreases cerebral injury after I/R. Neurological score (a) and PET imaging (b) in the sham, vehicle-ischemia, and Sac-1004-ischemia groups 1 day after I/R. Severe neurological deficits were observed, and 18F-FDG uptake (asterisk) was significantly decreased in the vehicle-ischemia group. However, in the Sac-1004-ischemia group, neurological deficits were significantly reduced and 18F-FDG uptake was increased compared with those in the vehicle-ischemia group. c Relative analysis as percentage values of 18F-FDG uptake groups 1 day after I/R (n = 7 per group; *** P < 0. vs sham group, ### P < 0.001 vs vehicle-ischemia group). TTC staining (d) in the sham, vehicle-ischemia, and Sac-1004-ischemia groups on days 1 and 4 post ischemia. Severe infarction was easily observed in the vehicle-ischemia group 1 and 4 days after I/R. However, infarct regions were significantly decreased in the Sac-1004-ischemia group. (e) Percentage change of infarct volume 1 and 4 days after I/R (n = 7 per group; *** P < 0.001 vs vehicle-ischemia group). The bars indicate the means ± SEM

Back to article page